JW (Cayman) Therapeutics Co. Ltd (2126.HK)
2126.HK Stock Price Chart
Explore JW (Cayman) Therapeutics Co. Ltd interactive price chart. Choose custom timeframes to analyze 2126.HK price movements and trends.
2126.HK Company Profile
Discover essential business fundamentals and corporate details for JW (Cayman) Therapeutics Co. Ltd (2126.HK) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
3 Nov 2020
Employees
281.00
Website
https://www.jwtherapeutics.comCEO
Min Liu
Description
JW (Cayman) Therapeutics Co. Ltd, a clinical stage cell therapy company, focuses on developing, manufacturing, and commercializing cell-based immunotherapies for hematological cancers and solid tumors. The company offers cell-based immunotherapies, including CAR-T treatments, which is a treatment method that uses human immune cells to fight cancer. Its lead product candidate is Carteyva (relmacabtagene autoleucel), an anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy for the treatment of a range of hematological cancers. The company's pipeline products include JWCAR129, an autologous CAR-T therapy for the treatment of multiple myeloma; JWATM204, a TCR T-cell therapy candidate for the treatment of HCC; and JWATM203, an autologous T-cell receptor mimic T-cell therapy targeting alpha-fetoprotein for the treatment of hepatocellular carcinoma. JW (Cayman) Therapeutics Co. Ltd was founded in 2016 and is headquartered in Shanghai, the People's Republic of China.
2126.HK Financial Timeline
Browse a chronological timeline of JW (Cayman) Therapeutics Co. Ltd corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 27 Mar 2026
Earnings released on 27 Aug 2025
EPS came in at -$0.70 , while revenue for the quarter reached $116.53M .
Earnings released on 27 Mar 2025
EPS came in at -$0.90 falling short of the estimated -$0.70 by -28.10%, while revenue for the quarter reached $75.96M , missing expectations by -45.79%.
Earnings released on 28 Aug 2024
EPS came in at -$0.62 surpassing the estimated -$0.69 by +9.16%, while revenue for the quarter reached $93.23M , missing expectations by -19.45%.
Earnings released on 20 Mar 2024
EPS came in at -$1.04 falling short of the estimated -$0.89 by -16.86%, while revenue for the quarter reached $95.31M , missing expectations by -66.99%.
Earnings released on 29 Aug 2023
EPS came in at -$1.00 falling short of the estimated -$0.92 by -8.94%, while revenue for the quarter reached $94.88M , missing expectations by -46.50%.
Earnings released on 26 Apr 2023
EPS came in at -$1.15 falling short of the estimated -$1.13 by -1.85%, while revenue for the quarter reached $90.77M , missing expectations by -77.64%.
Earnings released on 30 Aug 2022
EPS came in at -$1.23 surpassing the estimated -$1.34 by +7.85%, while revenue for the quarter reached $77.27M , beating expectations by +12.07%.
Earnings released on 31 Dec 2021
EPS came in at -$1.28 falling short of the estimated -$0.82 by -55.34%, while revenue for the quarter reached $37.71M , missing expectations by -54.16%.
Earnings released on 30 Jun 2021
EPS came in at -$0.85 falling short of the estimated -$0.84 by -1.32%.
Earnings released on 31 Dec 2020
EPS came in at -$6.06 falling short of the estimated -$0.63 by -865.01%, while revenue for the quarter reached -$1.01M .
2126.HK Stock Performance
Access detailed 2126.HK performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.